Is Escherichia coli in a wound infection susceptible to doxycycline?

Doxycycline Susceptibility for E. coli in Wound Infections

E. coli in wound infections shows variable susceptibility to doxycycline, with only 30-74% of strains being susceptible, making it a suboptimal empirical choice for wound infections where E. coli is suspected.

Key Evidence from FDA Drug Labeling

The FDA label explicitly states that "many strains of the following groups of microorganisms have been shown to be resistant to doxycycline" and specifically lists Escherichia coli among organisms requiring culture and susceptibility testing before use 1. This is critical—doxycycline is NOT recommended for empirical treatment of E. coli infections without documented susceptibility.

Clinical Susceptibility Data

The resistance patterns are concerning:

• Historical data (1980): 74% of E. coli strains were inhibited by 4 mg/L doxycycline 2
• More recent data (2009): Among ESBL-producing E. coli, only 52% remained susceptible to doxycycline 3
• Contemporary resistance (2016): Only 30% of ESBL-producing and 50% of carbapenem-resistant E. coli were susceptible to doxycycline 4

This demonstrates progressive resistance over time, making doxycycline increasingly unreliable for E. coli coverage.

Guideline Recommendations for Wound Infections

The IDSA guidelines for skin and soft tissue infections do not recommend doxycycline as first-line therapy for typical wound infections 5. Doxycycline is listed specifically for:

• Animal bites (excellent activity against Pasteurella multocida, though some streptococci are resistant)
• Human bites (good activity against Eikenella species, staphylococci, and anaerobes)

For wounds where E. coli is a likely pathogen, the guidelines favor beta-lactam/beta-lactamase inhibitor combinations (amoxicillin-clavulanate, ampicillin-sulbactam) or fluoroquinolones 5.

Critical Clinical Pitfalls

Do not use doxycycline empirically for wound infections when E. coli is suspected without culture confirmation. The major risks include:

• High baseline resistance: 50-70% of E. coli strains may be resistant
• ESBL producers: Only 30-52% susceptibility in these increasingly common strains 3, 4
• Multidrug-resistant isolates: Extensive resistance documented in wound isolates, particularly after 5 years of antibiotic pressure 6

When Doxycycline May Be Appropriate

Doxycycline can be considered for E. coli wound infections only when:

1. Culture and susceptibility testing confirms susceptibility
2. The patient has documented beta-lactam allergy
3. Alternative agents (fluoroquinolones, aminoglycosides) are contraindicated

Combination therapy may enhance activity: When combined with amikacin, doxycycline showed synergistic effects against 80% of multidrug-resistant E. coli isolates 4, though this requires further clinical validation.

Practical Algorithm

For suspected E. coli wound infection:

1. Obtain wound culture before starting antibiotics
2. Empirical therapy: Use amoxicillin-clavulanate, fluoroquinolone (ciprofloxacin/levofloxacin), or third-generation cephalosporin—NOT doxycycline 5
3. Adjust based on culture: Switch to doxycycline only if susceptibility confirmed and patient factors favor its use
4. Monitor clinical response: If using doxycycline, ensure clinical improvement within 48-72 hours

The FDA mandate for susceptibility testing before using doxycycline for E. coli infections reflects the high and increasing resistance rates that make empirical use clinically inappropriate 1.